Camargo Pharmaceutical Services, a leading drug development organization specializing in the 505(b)(2) approval pathway, joined inPack to present a seminar, “Non-Clinical and Clinical Study Design Factors in a Clinical Trial Protocol,” on Dec. 9 in Tel Aviv, Israel.
“Israel has relatively high levels of generic production and pharmaceutical exporting, which is why we focused on how to conduct studies that fulfill Israeli regulations while also meeting the FDA’s requirements,” said Ken Phelps, president and CEO of Camargo.
Help employers find you! Check out all the jobs and post your resume.
